WuXi Biologics differentiates itself from other ... in these platforms is reflected in a recent license agreement with GSK on multiple novel bi- and multi-specific T-cell engager antibodies.

WuXi Biologics differentiates itself from other ... in these platforms is reflected in a recent license agreement with GSK on multiple novel bi- and multispecific T-cell engager antibodies.

WuXi Biologics reports 32.5% North American revenue growth in 2024, driven by deals with BioNTech and Candid Therapeutics, ...

WuXi Biologics (2269.HK), a leading global CRDMO, has once again earned top recognition at the 2025 CDMO Leadership Awards, ...

SHANGHAI, March 23, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has ...

CORRECTION: WuXi Biologics has disputed a claim by WBJ construction has stopped at its Worcester facility. An earlier version of this article incorrectly conflated details involving WuXi Biologics ...